GLP-1 Drugs and Eating Disorders: A Hidden Risk in the Weight Loss Revolution
By Donnisa Edmonds, C2ST Intern, University of Chicago
In 2021, the FDA announced that they had approved Wegovy, a GLP-1 receptor agonist, as a treatment for chronic weight management. Since then, it feels like every pharmaceutical company has jumped at any opportunity to push their own GLP-1 drug for weight loss or weight management. In turn, use of these medications has skyrocketed. Recent reports suggest that as of 2022, 12% of adults in the United States have taken a GLP-1 agonist for weight loss at some point.
These medications are widely viewed as a win for people struggling with weight loss. However, many are also concerned about their long-term physical and mental effects, particularly for people with eating disorders.
To properly discuss these concerns, it’s important to first understand how GLP-1 drugs actually work.
Continue reading “GLP-1 Drugs and Eating Disorders: A Hidden Risk in the Weight Loss Revolution”